Skip to main content

Advertisement

Table 1 Demographic and symptom characteristics of study population at the start of the trial

From: Urox containing concentrated extracts of Crataeva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root, in the treatment of symptoms of overactive bladder and urinary incontinence: a phase 2, randomised, double-blind placebo controlled trial

Variable Placebo Treatment
Participants 75 75
Sex (Female %) 48 (64%) 40 (53%)
Age (years; mean ± SD) 62.48 ± 13.70 64.55 ± 12.42
Weight (kg; mean ± SD) 79.23 ± 22.47 78.53 ± 18.94
Day frequency ≥ 10 (n,%) 57 (76%) 50 (67%)
Nocturia ≥2 (n,%) 60 (80%) 70 (93%)
Urgency ≥2 (n,%) 62 (83%) 63 (84%)
Urgency incontinence≥1 (n,%) 33 (44%) 32 (43%)
Stress incontinence ≥1 (n,%) 9 (12%) 10 (13%)
Any incontinence ≥1 (n,%) 42 (56%) 35 (47%)
Only two symptoms (n,%) 25 (30%) 26 (35%)
Only three symptoms (n,%) 29 (39%) 30 (30%)
All four symptoms (n,%) 21 (28%) 19 (25%)
  1. Symptoms include urinary day frequency (≥10/day), nocturia (≥2/night), urgency (≥2/day), and incontinence (≥1/day) for ≥6 months prior to enrolling in the study; any incontinence includes urgency, stress and other incontinence